Loading
institutionsInstitution
QIMR Berghofer Medical Research Institute
Queensland's medical research institute, a world leader in melanoma and skin cancer genetics, cancer epidemiology and adoptive T-cell therapy for virus-associated cancers.
Also called: QIMRQueensland Institute of Medical Research
Overview
QIMR Berghofer was founded in 1945 as the Queensland Institute of Medical Research and works alongside the Royal Brisbane and Women's Hospital in Herston. Its cancer research is anchored in genetic epidemiology, with leading roles in melanoma and skin cancer genetics (Nicholas Hayward, David Whiteman), the QSkin cohort, and the Australian breast and ovarian cancer family studies (Georgia Chenevix-Trench, kConFab collaborations), and in immunology, where Rajiv Khanna's group developed EBV- and CMV-specific T-cell therapies for nasopharyngeal carcinoma and glioblastoma and Mark Smyth's laboratory shaped NK-cell and checkpoint immunology. The institute operates a GMP cell therapy facility (Q-Gen) and a clinical trials centre.
Location
Brisbane, AU
Type
research institute · University of Queensland
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#240 · 26 points (0 Newsweek + 0 NCI + 26 from 13 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to QIMR Berghofer Medical Research Institute, including child institutions. 281 works · 3,430 citations · 79% open access · 10% clinical trials · 5% reviews.
Oncology works per year
492022
562023
562024
612025
592026
Most works
- David C. Whiteman39 works
- Catherine M. Olsen31 works
- Nirmala Pandeya26 works
- Rachel Ε. Neale22 works
- Nicola Waddell21 works
- Matthew H. Law18 works
- Adèle C. Green18 works
- John V. Pearson15 works
- Kiarash Khosrotehrani13 works
- B. Mark Smithers12 works
Most cited
- Melanoma and skin cancer genetics
- Cancer epidemiology and cohorts
- Virus-specific T-cell therapy
- Q-Gen cell manufacturing
Similar pages
- PersonRachel Michaelson-Cohen
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer, HR-positive / HER2-negative breast cancer.
- InstitutionUniversity of Malaya Medical Centre
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Head and neck squamous cell carcinoma, HR-positive / HER2-negative breast cancer.
- IdeaEngineered immune surveillance: long-lived programmed immune cells that patrol for early cancer
Shares CAR-NK & CAR-macrophage, TCR-T cell therapy, BRCA1 / BRCA2 (HRD).
- IdeaGo back to families of women who died of ovarian cancer and offer BRCA testing
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.
- PersonEitan Friedman
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer, HR-positive / HER2-negative breast cancer.
- PersonEphrat Levy-Lahad
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer, HR-positive / HER2-negative breast cancer.
- IdeaPopulation germline screening for hereditary cancer genes with cascade testing
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer, HR-positive / HER2-negative breast cancer.
- Key paperFounder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.